| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | S-1/A |
| Revenues: |
| Royalty And Licensing Revenue | 15.5 | 10.0 | 25.8 | | | | |
| Upneeq | 34.2 | 7.5 | 0.5 | | | | |
| Osmolex | | | 1.4 | | | | |
| Total revenues | 49.7 | 17.5 | 27.8 | 240.0 | 263.7 | 245.7 | |
| Revenue growth [+] | 184.1% | -37.0% | -88.4% | -9.0% | 7.3% | | |
| Royalty And Licensing Revenue | 55.0% | -61.3% | | | | | |
| Upneeq | 355.6% | 1327.9% | | | | | |
| Product Revenue | | | -99.2% | -9.9% | | | |
| Cost of goods sold | 9.5 | 3.6 | 3.3 | 111.6 | 140.1 | 125.2 | |
| Gross profit | 40.3 | 13.9 | 24.5 | 128.4 | 123.6 | 120.6 | |
| Gross margin | 81.0% | 79.3% | 88.1% | 53.5% | 46.9% | 49.1% | |
| Selling, general and administrative | 82.0 | 87.5 | 72.8 | 93.0 | 74.2 | 57.0 | |
| Research and development | 4.0 | 6.9 | 13.4 | 32.3 | 43.7 | 42.7 | |
| Other operating expenses | | -19.8 | | | | 73.0 | |
| EBITDA [+] | -45.3 | -52.5 | -40.7 | 60.1 | 87.3 | -5.6 | |
| EBITDA growth | -13.7% | 28.9% | -167.8% | -31.2% | -1653.1% | | |
| EBITDA margin | -91.1% | -300.0% | -146.7% | 25.0% | 33.1% | -2.3% | |
| Depreciation | 0.4 | 8.2 | 21.0 | 4.4 | 4.5 | 3.1 | |
| EBITA | -45.7 | -60.7 | -61.7 | 55.7 | 82.8 | -8.7 | |
| EBITA margin | -91.9% | -346.7% | -222.4% | 23.2% | 31.4% | -3.5% | |
| Amortization of intangibles | | | | 52.7 | 77.1 | 43.4 | |
| EBIT [+] | -45.7 | -60.7 | -61.7 | 3.1 | 5.7 | -52.1 | |
| EBIT growth | -24.7% | -1.7% | -2123.0% | -46.3% | -110.9% | | |
| EBIT margin | -91.9% | -346.7% | -222.4% | 1.3% | 2.2% | -21.2% | |
| Non-recurring items [+] | 13.3 | 22.1 | 28.9 | 283.7 | 104.2 | | |
| Asset impairment | 13.3 | 7.9 | 28.9 | 283.7 | 104.2 | | |
| Loss (gain) on sale of assets | | 5.6 | | | | | |
| Loss (gain) on sale of business | | 4.1 | | | | | |
| Interest expense | 3.1 | 3.0 | 4.1 | 18.2 | 20.8 | 29.1 | |
| Interest expense | 3.1 | 3.0 | 4.1 | 18.2 | 20.8 | 29.1 | |
| Other income (expense), net [+] | 10.4 | 3.3 | 0.0 | 0.9 | 0.7 | -4.5 | |
| Change in fair value of warrants | -1.3 | -5.6 | | | | | |
| Other | | | | | | -4.5 | |
| Pre-tax income | -51.7 | -82.5 | -94.8 | -298.0 | -118.7 | -85.6 | |
| Income taxes | 0.0 | 0.3 | -5.8 | -27.1 | -9.0 | -44.5 | |
| Tax rate | 0.0% | | 6.1% | 9.1% | 7.6% | 52.0% | |
| Net income | -51.7 | -64.9 | -79.6 | -270.9 | -109.7 | -41.1 | |
| Net margin | -104.0% | -371.0% | -286.7% | -112.9% | -41.6% | -16.7% | |
| |
| Basic EPS [+] | ($0.58) | ($1.23) | ($1.47) | ($5.17) | ($2.42) | ($0.96) | |
| Growth | -53.2% | -16.2% | -71.6% | 113.5% | 152.3% | | |
| Diluted EPS [+] | ($0.58) | ($1.23) | ($1.47) | ($5.17) | ($2.42) | ($0.96) | |
| Growth | -53.2% | -16.2% | -71.6% | 113.5% | 152.3% | | |
| |
| |
| Shares outstanding (basic) [+] | 89.8 | 67.4 | 60.7 | 52.4 | 45.3 | 42.9 | |
| Growth | 33.3% | 11.0% | 15.8% | 15.7% | 5.6% | | |
| Shares outstanding (diluted) [+] | 89.8 | 67.4 | 60.7 | 52.4 | 45.3 | 42.9 | |
| Growth | 33.3% | 11.0% | 15.8% | 15.7% | 5.6% | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |